International journal of women's health · 2026
Integrative Mendelian Randomization and Whole-Blood Transcriptomic Analysis Implicate a Myeloid-Inflammation Axis in Polycystic Ovary Syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fu Yiman, Li Weihao, Ma Lin
Аннотация
BACKGROUND: Immune dysregulation and low-grade inflammation are central to the pathophysiology of polycystic ovary syndrome (PCOS). However, putative causal relationships inferred from genetic instruments and their consistency with transcriptomic readouts remain underexplored.
METHODS: We conducted two-sample Mendelian randomization (MR) to estimate potential causal relationships between 731 immune immunophenotypes and PCOS. In an independent, small whole-blood transcriptomic dataset (Gene Expression Omnibus [GEO]: GSE54248; PCOS n=4, controls n=4), we applied gene-signature-based deconvolution (xCell and Microenvironment Cell Populations-counter [MCP-counter]) and single-sample pathway scoring to profile myeloid cell composition and IL-6/JAK/STAT3 and tumor necrosis factor-α/nuclear factor κB (TNF-α/NF-κB) pathway activity. Robustness of the MR findings was examined by standard sensitivity analyses.
RESULTS: MR indicated opposite-direction associations for key myeloid traits: higher absolute monocyte count was inversely associated with PCOS risk (odds ratio [OR] per standard deviation [SD] increase 0.52, 95% confidence interval [CI] 0.39-0.69, P=6.21x10-6, false discovery rate [FDR] q=0.002), whereas higher CD33+HLA-DR+ absolute count was positively associated with PCOS (OR per SD 1.61, 95% CI 1.27-2.03, P=6.39x10-5, FDR q=0.024). In the exploratory GSE54248 dataset, transcriptomic deconvolution suggested myeloid enrichment in PCOS, with tendencies toward higher signatures of monocytes, macrophages (M1/M2), and myeloid dendritic cells (DCs) and higher composite myeloid scores versus controls. Single-sample pathway analyses were consistent with increased IL-6/JAK/STAT3 and TNF-α/NF-κB activities in PCOS, with large effect sizes (Cohen's d=2.27 and 2.16, respectively) but modest P-values (Wilcoxon P=0.057; Benjamini-Hochberg FDR q=0.143 for both pathways).
CONCLUSION: Genetic and transcriptomic evidence jointly support the concept of a myeloid-inflammation axis in PCOS. The inverse MR association for absolute monocyte count alongside positive risk for CD33+HLA-DR+ compartments, together with cross-cohort evidence of myeloid enrichment and inflammatory pathway activation, is compatible with a potential mechanistic link between immune imbalance and PCOS and provides a hypothesis-generating framework for future therapeutic investigation.
METHODS: We conducted two-sample Mendelian randomization (MR) to estimate potential causal relationships between 731 immune immunophenotypes and PCOS. In an independent, small whole-blood transcriptomic dataset (Gene Expression Omnibus [GEO]: GSE54248; PCOS n=4, controls n=4), we applied gene-signature-based deconvolution (xCell and Microenvironment Cell Populations-counter [MCP-counter]) and single-sample pathway scoring to profile myeloid cell composition and IL-6/JAK/STAT3 and tumor necrosis factor-α/nuclear factor κB (TNF-α/NF-κB) pathway activity. Robustness of the MR findings was examined by standard sensitivity analyses.
RESULTS: MR indicated opposite-direction associations for key myeloid traits: higher absolute monocyte count was inversely associated with PCOS risk (odds ratio [OR] per standard deviation [SD] increase 0.52, 95% confidence interval [CI] 0.39-0.69, P=6.21x10-6, false discovery rate [FDR] q=0.002), whereas higher CD33+HLA-DR+ absolute count was positively associated with PCOS (OR per SD 1.61, 95% CI 1.27-2.03, P=6.39x10-5, FDR q=0.024). In the exploratory GSE54248 dataset, transcriptomic deconvolution suggested myeloid enrichment in PCOS, with tendencies toward higher signatures of monocytes, macrophages (M1/M2), and myeloid dendritic cells (DCs) and higher composite myeloid scores versus controls. Single-sample pathway analyses were consistent with increased IL-6/JAK/STAT3 and TNF-α/NF-κB activities in PCOS, with large effect sizes (Cohen's d=2.27 and 2.16, respectively) but modest P-values (Wilcoxon P=0.057; Benjamini-Hochberg FDR q=0.143 for both pathways).
CONCLUSION: Genetic and transcriptomic evidence jointly support the concept of a myeloid-inflammation axis in PCOS. The inverse MR association for absolute monocyte count alongside positive risk for CD33+HLA-DR+ compartments, together with cross-cohort evidence of myeloid enrichment and inflammatory pathway activation, is compatible with a potential mechanistic link between immune imbalance and PCOS and provides a hypothesis-generating framework for future therapeutic investigation.